Tesamorelin: reference dosing schedule
> Updated:
Calculate the Tesamorelin dose
The calculator is already set up for Tesamorelin — adjust the dose or diluent volume for your vial.
Human dosing
| Period / condition | Dose | Note |
|---|---|---|
| Main regimen | 2 mg subcutaneously once daily | Fixed dose, no titration |
| Upper limit | 2 mg per day | Maximum in this schedule |
Background on the molecule, its mechanism and primary sources is covered in the monograph.
Practical dosing and effect details
In a trial by Falutz and colleagues (New England Journal of Medicine, 2007), 412 participants with HIV and abdominal fat accumulation received either 2 mg of tesamorelin subcutaneously once daily or placebo for 26 weeks.
Visceral adipose tissue on CT decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group (p<0.001). Insulin-like growth factor 1 (IGF-1), a biomarker of GHRH-receptor activation, rose 81.0% in the tesamorelin group versus a 5.0% decrease with placebo, tying that specific dose to a measurable biological effect.
The effect held only while dosing continued: researchers assessed outcomes at week 26 of continuous daily administration, not after a short course, so consistency rather than a single dose drove the result. The trial was conducted in adults with HIV-associated lipodystrophy; this is not evidence of an effect in other populations or for other uses. The schedule on this page reproduces the trial dose as reference information, not a medical recommendation.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 20 mg vial.Tesamorelin20 mg+ 2 mlDiluent
- 2Get the concentrationExample: 20 mg in 2 ml =Tesamorelin10 mg/ml(10,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 1 mg dose:1 mg = 0.1 ml= 10 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
Tesamorelin: reference regimens
Tesamorelin is a GHRH analog given by subcutaneous injection (typically into the abdomen).
Tesamorelin dosing in the clinical trial was fixed at 2 mg subcutaneously once daily, unlike many research peptides where the schedule is set individually for each protocol.
More scientific background in the Tesamorelin monograph
Notes and safety
- • Tesamorelin is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
Tesamorelin